Ciprofloxacin was compared with erythromycin for the eradication of Campylobacter species that were chronically excreted in the stools of marmosets (Saguinus labiatus labiatus, SaguinusffuscicoUis nigrifrons, and Saguinusfuscicolis iligeri). Stool cultures were negative within 48 h of the beginning of treatment with either agent. Within 10 days after the end of therapy, however, Campylobacter species were again isolated from the stools of six animals that had received erythromycin. During an 8-week follow-up period, no animal that had received ciprofloxacin relapsed. High levels of ciprofloxacin in the stool (mean, 49.2 ,ug/g) possibly contributed to the efficacy of this agent.
Ciprofloxacin is a new fluoroquinoline structurally related to nalidixic acid. This agent has excellent in vitro activity against many enteric bacterial pathogens, including Shigella, Salmonella, Vibrio, and Yersinia species and Escherichia coli (3) . Ciprofloxacin was the most active of 12 antimicrobial agents that we tested against 27 isolates of Campylobacterjejuni (the MIC for 90% of the isolates was 0.25 ,ug/ml), 31 isolates of Campylobacter coli (the MIC for 90% of the isolates was 0.25 ,ug/ml), and 30 isolates of Campylobacter fetus subsp. fetus (the MIC for 90% of the isolates was 1.0 ,ug/ml) (2) . In that study, ciprofloxacin was more active than erythromycin, currently considered the agent of choice for Campylobacter-associated diarrhea. Ciprofloxacin is not completely absorbed after oral administration and conceivably could affect Campylobacter species in the gut via both systemic and local action. Our marmoset colony provided a sizable group of animals chronically excreting Campylobacter species in their feces to test this concept and relate it to the performance of erythromycin.
MATERIALS AND METHODS Animals. Twenty-three marmosets were studied. These animals were part of the marmoset colony of RushPresbyterian-St Luke's Medical Center. Study animals represented three species: Saguinus fuscicollis nigrifrons, Saguinusfuscicollis illigeri, and Saguinus labiatus labiatus. Eighteen ofthe animals were colony bred; the remainder were feral. Feral animals had been in the colony for at least 2 years. No animal was used concurrently for other studies; none had received an antimicrobial agent in the 12 weeks preceding this study or had recently had diarrhea. Animals were fed a canned monkey diet (Science Diet Canned Marmoset, Hills Pet Products, Topeka, Kans.) supplemented by fresh fruit and vitamins. Approximately 30 to 40% of the animals in our colony have Campylobacter species in their feces. The occurrence of Campylobacter organisms is not species specific. We have previously cultured the food given the * Corresponding author.
animals and have never documented this as a source of infection.
Animals were divided into two groups. Group 1 (11 animals) received ciprofloxacin, and group 2 (12 animals) received erythromycin. Animals weighed approximately 0.5 kg each. AR study animals had had C. jejuni or C. coli isolated from their stools at the onset of treatment and at least three times in the preceding 2 weeks. Each group had a similar mixture of the two Campylobacter species, the three marmoset species, and a similar sex distribution. Animals were housed in separate cages, while the two groups were placed in separate rooms. Cages were separated sufficiently to make fecal cross-contamination unlikely. Animal handlers observed mask, glove, and gown isolation procedures. The same handlers were used for both groups.
Antimicrobial agents and study protocol. Ciprofloxacin and erythromycin were administered to respective groups by gastric tube in a 5-mg dose twice per day for 5 days. This dosage was chosen to approximate the dosages of these agents used in humans. The agents were administed at approximately 7:30 a.m and 4:00 p.m. each day. Each antibiotic was administered in a solution of sterile saline (1.0 ml) and followed by an additional 1.0 ml of sterile saline to rinse the tube. Fresh stool specimens were collected daily from the trays at the bottom of the cages. After specimen collection, these trays were cleaned. On day 3 of therapy, all animals were transferred to steam-cleaned cages. Stool cultures were performed on all animals three times weekly for 4 weeks following therapy, and once weekly for 4 additional weeks.
Ciprofloxacin serum and stool levels. A single serum sample was obtained from animals (femoral vein puncture) in the ciprofloxacin group 1 h after dose 5. Each animal in the ciprofloxacin group had a portion of stool frozen on days 2 through 5 of treatment and on days 2 and 4 after treatment stopped. These serum and stool specimens were stored at -70°C before testing.
Ciprofloxacin serum and stool levels were measured by biological assay. Trypticase soy broth (BBL Microbiology Systems, Cockeysville, Md.) that was seeded with several ANTIMICROB. AGENTS CHEMOTHER. (6) . C. jejuni and C. coli were separated by the rapid hippurate method of Hwang and Ederer (5) . In vitro susceptibilities of all Campylobacter isolates were established with standard agar dilution techniques and appropriate microbiologic controls. All pretreatment isolates in group 1 were susceptible to ciprofloxacin (MICs for all isolates were <0.25 p.g/ml). In group 2, erythromycin yielded the following MICs: 8 pbg/ml for two C. coli isolates, 4 ,ug/ml for two other C. coli isolates, 0.5 ,ug/ml for one C. coli isolate, and 0.125 ,ug/ml for seven C. jejuni isolates. Serotyping of posttreatment isolates was performed by one of us (J.P.) by standard methods.
RESULTS
All animals tolerated treatment without observable side effects. In both groups, stool cultures for Campylobacter species became negative within 48 h after the initial treatment. During the 8-week follow-up period, Campylobacter species were not isolated from any animal that received ciprofloxacin. However, the stool specimens of six animals that had received erythromycin yielded Campylobacter isolates by day 10 of posttreatrment; recurrence in four of these animals was evident 2 days after the end of treatment. This difference between ciprofloxacin and erythromycin was significant (P < 0.01, Fisher's exact test). All six posttreatment isolates were susceptible to both erythromycin (MIC < 0.125 jig/ml, Table 1 ) and ciprofloxacin (MIC < 0.125 ,jg/ml).
Posttreatment isolates included both hippurate-positive and -negative organisms aind represented three different Campylobacter serotypes. Animals not responding to treatment continued to excrete Campylobacter organisms throughout an 8-week follow-up period.
Serum and stool levels of ciprofloxacin were obtained from the eleven animals receiving this agent (Table 2) . Serum levels for the single determinationi ranged from 0.94 to 3.40 jg/ml, with a mean of 2.06 ,ug/ml. Stool levels ranged from 8.1 to 190.0 ,g of ciprofloxacin per g of stool, with a DISCUSSION Ciprofloxacin was effective in eradicating Campylobacter organisms from the feces of these animals. Ciprofloxacin stool levels were relatively steady during dosage. The occasional variability might have been due to daily differences in the amount of food or water taken in (possibly affecting drug absorption) or in transit time. The single serum ciprofloxacin level obtained demonstrates that all the animals absorbed the drug. These serum levels are similar to those of humans after a 500-mg oral dose. (1) .
While the major goal of this study was to evaluate the in vivo efficacy of ciprofloxacin, the failure or erythromycin in 6 of 12 animals is significant. Ciprofloxacin is 10-fold more active-than erythromycin in vitro. Stool levels of ciprofloxacin commonly exceeded the MICs for these organisms by 100-fold. These high ratios of ciprofloxacin stool levels to MICs may have contributed to the differences seen between the two groups. During this study we did not measure erythromycin stool levels, so no direct comparison is possible. In humans treated daily with erythromycin, stool levels of the antibiotic frequently exceed 250 ,ug/g (4, 8) ; this suggests that the levels of erythromycin in the guts of our test animals should not have been a factor. However, we have since re-treated six animals with the same dosage of erythromycin and found mean antibiotic stool levels of only 14.4 ,ug/g (range, 4.6 to 27.9 ,g/g), a level that exceeds the MIC for several pretreatment isolates by less than twofold.
Erythromycin had an MIC for several posttreatment isolates that was significantly different from the MIC for the corresponding pretreatment isolate (Table 1 , marmosets 3 and 4). Possibly these animals were originally infected with more than one Campylobacter species. These organisms are morphologically similar, and pretreatment serotyping of every colony isolated was not feasible. While this may explain the variation in MICs, it does not explain the failure of erythromycin in these animals.
The serotyping of posttreatment isolates demonstrated that three different serotypes were present. This ruled out the possibility of a single animal relapsing and subsequently infecting other animals.
Recently, C. jejuni has been shown to survive for up to 7 days intraceilularly (7) . Possibly, the difference seen in our two groups is related to the comparative abilities of ciprofloxacin and erythromycin to penetrate mononuclear cells and kill organisms intracellularly.
In the dosages used, ciprofloxacin was superior to erythromycin in eradicating Campylobacter species in the intestinal tract of marmosets. The effectiveness of ciprofloxacin suggests that this agent might be useful in the treatment of Campylobacter-associated diarrhea in humans.
